Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
Revenue of Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
Revenue in 2023 (TTM): $5.75 B
According to Sun Pharmaceutical Industries Limited's latest financial reports the company's current revenue (TTM) is $5.75 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Sun Pharmaceutical Industries Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $5.75 B | $3.06 B | $1.64 B | $1.31 B | $1.13 B |
| 2022 | $5.13 B | $3.86 B | $1.43 B | $1.11 B | $1 B |
| 2021 | $4.55 B | $3.17 B | $793.87 M | $531.01 M | $387.8 M |
| 2020 | $3.93 B | $2.76 B | $592.31 M | $331.71 M | $344.09 M |
| 2019 | $3.83 B | $2.59 B | $866.54 M | $593.61 M | $446.12 M |
| 2018 | $3.4 B | $2.3 B | $720.92 M | $451.49 M | $315.84 M |
| 2017 | $3.09 B | $2.04 B | $640.31 M | $412.24 M | $256.13 M |
| 2016 | $3.55 B | $2.44 B | $1.26 B | $1.07 B | $825.24 M |
| 2015 | $3.29 B | $2.4 B | $957.15 M | $801.65 M | $558.81 M |
| 2014 | $3.23 B | $2.31 B | $968.87 M | $758.71 M | $537.89 M |
| 2013 | $1.9 B | $1.5 B | $883.53 M | $543.07 M | $372.25 M |
| 2012 | $1.33 B | $1.03 B | $556.27 M | $512.06 M | $353.48 M |
| 2011 | $948.12 M | $713.27 M | $435.57 M | $397.72 M | $306.57 M |
| 2010 | $677.96 M | $504.87 M | $272.25 M | $241.23 M | $215.19 M |
| 2009 | $462.6 M | $332.52 M | $185.82 M | $167.65 M | $159.61 M |
| 2008 | $506.24 M | $404.86 M | $245.57 M | $230.97 M | $222.53 M |
| 2007 | $397.73 M | $312.16 M | $201 M | $189.52 M | $183.77 M |
| 2006 | $252.64 M | $184.3 M | $108.4 M | $98.76 M | $99.55 M |
| 2005 | $193.95 M | $136.22 M | $77.96 M | $70.73 M | $67.89 M |
| 2004 | $141.99 M | $103.67 M | $54.69 M | $49.87 M | $47.45 M |
| 2003 | $116.67 M | $88.4 M | $48.56 M | $45.17 M | $39.2 M |